Report from Turkey - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Report from Turkey


Pharmaceutical Technology
Volume 36, Issue 11, pp. 18-20

Turkey has a strong infrastructure for medicines manufacture with around 300 pharmaceutical producers, making it the seventh largest pharmaceutical industry in Europe and 16th in the world. The country has well-established universities providing a basis for R&D activities.

Above all, Turkey is strategically located at the crossroads between Europe and Asia. It has the logistical connections to supply Europe, which has annual pharmaceutical imports of $264 billion; Russia with imports of $11 billion; Central Asia and the Caucasus with $2 billion; and the Middle East and North Africa with $14 billion.

To realize the potential of these benefits by attracting large amounts of investment, the industry argues that the government must first introduce a more sustainable drugs-pricing policy. Currently, Turkey's medicines prices are among the lowest in the world.

The country has had some recent investment successes. These include Amgen's $700-million takeover of Mustafa Nevzat Pharmaceuticals, a Turkish generics producer; the formation of a partnership between Otsuka of Japan and Abdi Ibrahim of Turkey; and a decision by Zentiva, a Czech subsidiary of Sanofi, to make Turkey a production base for generic drugs.

A survey earlier this year by AIFD, however, found that price cuts by the government have been holding back investment. More than half of 23 research-based pharmaceutical companies said they had had to cancel investments because of government measures, mainly on prices.

Another problem has been a decision by the government not to recognise GMP certificates from the EU and the US. Instead, foreign production facilities have to be inspected first by Turkish officials before Turkish marketing licences for medicines can be granted.

An AIFD survey in April 2012 found that approvals of almost 300 medicines of foreign research-based companies were being delayed because of the lengthy time it was taking to gain GMP certification. "The GMP issue has to be sorted out through mutual recognition agreements with the EU and US," says an IEIS official.

Another drawback for Turkey is a poor reputation for IP protection in which it is rated 70th in the world. In some key areas, the country has a lot of ground to make up before its pharmaceutical manufacturing industry can attain a top global ranking.

References

1. PwC and AIFD, Turkey's Pharmaceutical Sector—Vision 2023 Report, Strategy Document (Sept. 2012).

2. Boston Consulting Group, Partnering with the Government to Globalize the Turkish Pharmaceutical Industry (Nov. 2011).

—Sean Milmo is a freelance writer based in Essex, UK


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: Pharmaceutical Technology,
Click here